Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 830

1.

Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Moreira EG, Boll KM, Correia DG, Soares JF, Rigobello C, Maesd M.

Curr Neuropharmacol. 2018 Dec 27. doi: 10.2174/1570159X17666181227164947. [Epub ahead of print]

PMID:
30592255
2.

NLRP3 inflammasome in the pathophysiology of hemorrhagic stroke: A Review.

Luo Y, Reis C, Chen S.

Curr Neuropharmacol. 2018 Dec 27. doi: 10.2174/1570159X17666181227170053. [Epub ahead of print]

PMID:
30592254
3.

Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies.

Aliev G.

Curr Neuropharmacol. 2018 Dec 27. doi: 10.2174/1570159X17666181227163039. [Epub ahead of print]

PMID:
30592253
4.

Valproic acid and epilepsy: from molecular mechanisms to clinical evidences.

Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C.

Curr Neuropharmacol. 2018 Dec 27. doi: 10.2174/1570159X17666181227165722. [Epub ahead of print]

PMID:
30592252
5.

The Era of Cerebellar Therapy.

Mitoma H, Manto M.

Curr Neuropharmacol. 2019;17(1):3-6. doi: 10.2174/1570159X1701181129111212.

PMID:
30582473
6.

Preface.

Salt TE.

Curr Neuropharmacol. 2019;17(1):2. doi: 10.2174/1570159X1701181129110951.

PMID:
30582472
7.

Sense of Smell: Structural, Functional, Mechanistic Advancements and Challenges in Human Olfactory Research.

Sharma A, Kumar R, Aier I, Semwal R, Tyagi P, Varadwaj P.

Curr Neuropharmacol. 2018 Dec 5. doi: 10.2174/1570159X17666181206095626. [Epub ahead of print]

PMID:
30520376
8.

Neuroprotective role of hypothermia in hypoxic-ischemic brain injury: combined therapies using estrogen.

Toro-Urrego N, Vesga-Jiménez DJ, Herrera MI, Luaces JP, Capani F.

Curr Neuropharmacol. 2018 Dec 5. doi: 10.2174/1570159X17666181206101314. [Epub ahead of print]

PMID:
30520375
9.

Application of the Co-Agonist Concerted Transition Model to Analysis of GABAA Receptor Properties.

Germann AL, Steinbach JH, Akk G.

Curr Neuropharmacol. 2018 Dec 5. doi: 10.2174/1570159X17666181206092418. [Epub ahead of print]

PMID:
30520374
10.

Current drugs and potential future neuroprotective compounds for Parkinson's disease.

Carrera I, Cacabelos R.

Curr Neuropharmacol. 2018 Nov 27. doi: 10.2174/1570159X17666181127125704. [Epub ahead of print]

PMID:
30479218
11.

Evolving Mechanistic Concepts Of Epileptiform Synchronization And Their Relevance In Curing Focal Epileptic Disorders.

Lévesque M, Ragsdale D, Avoli M.

Curr Neuropharmacol. 2018 Nov 27. doi: 10.2174/1570159X17666181127124803. [Epub ahead of print]

PMID:
30479217
12.

Systematic Review of Food Addiction as Measured With the Yale Food Addiction Scale: Implications for the Food Addiction Construct.

Penzenstadler L, Soares C, Karila L, Khazaal Y.

Curr Neuropharmacol. 2018 Nov 7. doi: 10.2174/1570159X16666181108093520. [Epub ahead of print]

PMID:
30406740
13.

Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time.

Kotzalidis GD, Del Casale A, Simmaco M, Pancheri L, Brugnoli R, Paolini M, Gualtieri I, Ferracuti S, Savoja V, Cuomo I, De Chiara L, Mosca A, Sani G, Girardi P, Pompili M, Rapinesi C, On Behalf Of The Sapienza Group For The Study Of The Placebo Effect In Psychiatric Disorders.

Curr Neuropharmacol. 2018 Oct 26. doi: 10.2174/1570159X16666181026163922. [Epub ahead of print]

PMID:
30370851
14.

Special Issue on Programmed Cell Death in Stroke.

Hu Q.

Curr Neuropharmacol. 2018;16(9):1254. doi: 10.2174/1570159X1609181005102948. No abstract available.

PMID:
30328396
15.

Omics-based biomarkers for the early Alzheimer Disease diagnosis and reliable therapeutic targets development.

Pena-Bautista C, Baquero M, Vento M, Chafer-Pericas C.

Curr Neuropharmacol. 2018 Sep 26. doi: 10.2174/1570159X16666180926123722. [Epub ahead of print]

PMID:
30255758
16.

Alzheimer Disease - Future Therapy Based on Dendrimers.

Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutovа A, Baeesa SS, Avila-Rodriguez M, Ustyugov AA, Bachurin SO.

Curr Neuropharmacol. 2018 Sep 18. doi: 10.2174/1570159X16666180918164623. [Epub ahead of print]

PMID:
30227819
17.

Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.

Mitoma H, Manto M, Hampe CS.

Curr Neuropharmacol. 2019;17(1):33-58. doi: 10.2174/1570159X16666180917105033.

PMID:
30221603
18.

Traumatic Brain Injury altered Normal Brain Signaling Pathways: Implications for Novel Therapeutics approaches.

Rana A, Singh S, Sharma R, Kumar A.

Curr Neuropharmacol. 2018 Sep 11. doi: 10.2174/1570159X16666180911121847. [Epub ahead of print]

PMID:
30207236
19.

Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: a systematic review.

Costa IM, Lima FOV, Fernandes LCB, Norrara B, Neta FI, Alves RD, Cavalcanti JRLP, Lucena EES, Cavalcante JS, Rego ACM, Filho IA, Queiroz DB, Freire MAM, Guzen FP.

Curr Neuropharmacol. 2018 Sep 11. doi: 10.2174/1570159X16666180911123341. [Epub ahead of print]

PMID:
30207235
20.

Neuroprotective Strategies for Neurological Disorders by Natural Products: An update.

Rehman MU, Wali AF, Ahmad A, Shakeel S, Rasool S, Ali R, Rashid SM, Madkhali H, Ganaie MA, Khan R.

Curr Neuropharmacol. 2018 Sep 11. doi: 10.2174/1570159X16666180911124605. [Epub ahead of print]

PMID:
30207234

Supplemental Content

Loading ...
Support Center